Kamada Ltd. (NASDAQ:KMDA) Short Interest Down 17.8% in February

Kamada Ltd. (NASDAQ:KMDA) was the target of a significant drop in short interest during the month of February. As of February 27th, there was short interest totaling 136,757 shares, a drop of 17.8% from the February 12th total of 166,435 shares. Based on an average daily volume of 63,886 shares, the days-to-cover ratio is presently 2.1 days. Currently, 0.4% of the shares of the stock are sold short. Currently, 0.4% of the shares of the stock are sold short. Based on an average daily volume of 63,886 shares, the days-to-cover ratio is presently 2.1 days.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. HC Wainwright upped their target price on shares of Kamada from $11.00 to $13.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Benchmark reissued a “buy” rating on shares of Kamada in a research note on Thursday, March 12th. Wall Street Zen downgraded Kamada from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research note on Thursday, January 22nd. Finally, Stifel Nicolaus set a $11.00 target price on Kamada in a report on Wednesday, March 11th. Three analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, Kamada presently has a consensus rating of “Moderate Buy” and an average price target of $13.00.

Hedge Funds Weigh In On Kamada

Hedge funds and other institutional investors have recently made changes to their positions in the company. Aristides Capital LLC raised its holdings in shares of Kamada by 4.5% in the fourth quarter. Aristides Capital LLC now owns 33,015 shares of the biotechnology company’s stock valued at $233,000 after acquiring an additional 1,430 shares in the last quarter. NewEdge Advisors LLC grew its holdings in Kamada by 4.2% during the 3rd quarter. NewEdge Advisors LLC now owns 52,668 shares of the biotechnology company’s stock worth $366,000 after acquiring an additional 2,125 shares in the last quarter. ARK Investment Management LLC increased its position in Kamada by 1.2% during the 3rd quarter. ARK Investment Management LLC now owns 256,217 shares of the biotechnology company’s stock valued at $1,779,000 after purchasing an additional 2,943 shares during the period. Barclays PLC increased its position in Kamada by 417.1% during the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 3,862 shares during the period. Finally, Two Sigma Investments LP raised its holdings in shares of Kamada by 4.3% in the 3rd quarter. Two Sigma Investments LP now owns 109,589 shares of the biotechnology company’s stock valued at $761,000 after purchasing an additional 4,504 shares in the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Trading Down 0.7%

Shares of KMDA opened at $8.83 on Wednesday. The firm has a fifty day moving average price of $8.50 and a 200-day moving average price of $7.49. The firm has a market capitalization of $507.81 million, a P/E ratio of 25.23, a P/E/G ratio of 0.68 and a beta of 0.94. Kamada has a 12-month low of $5.54 and a 12-month high of $9.35.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Wednesday, March 11th. The biotechnology company reported $0.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.03). The company had revenue of $44.68 million during the quarter, compared to analysts’ expectations of $145.07 million. Kamada had a net margin of 11.19% and a return on equity of 7.72%. Analysts predict that Kamada will post 0.23 earnings per share for the current year.

Kamada Dividend Announcement

The company also recently disclosed an annual dividend, which will be paid on Monday, April 6th. Shareholders of record on Monday, March 23rd will be issued a dividend of $0.25 per share. This represents a yield of 292.0%. The ex-dividend date is Monday, March 23rd.

About Kamada

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma‐derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha‐1 antitrypsin augmentation therapy approved by the U.S.